Successful correction of hemophilia by CRISPR/Cas9 genome editing in vivo : delivery vector and immune responses are the key to success
Abstract
Comment on
CRISPR/Cas9-mediated somatic correction of a novel coagulator factor IX gene mutation ameliorates hemophilia in mouse. [EMBO Mol Med. 2016]
Domains
Human health and pathology
Origin : Publisher files allowed on an open archive
Loading...